{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T07:45:19Z","timestamp":1776584719753,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"CRUK","doi-asserted-by":"publisher","award":["C9759"],"award-info":[{"award-number":["C9759"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"CRUK","doi-asserted-by":"publisher","award":["A9766"],"award-info":[{"award-number":["A9766"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.radonc.2015.11.015","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T01:37:03Z","timestamp":1450316223000},"page":"471-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Continuous hyperfractionated accelerated radiotherapy \u2013 Escalated dose (CHART-ED): A phase I study"],"prefix":"10.1016","volume":"118","author":[{"given":"Matthew Quintin Fielding","family":"Hatton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-5673","authenticated-orcid":false,"given":"Robert","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John David","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4710-4291","authenticated-orcid":false,"given":"Sally A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip James","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten Eleanor","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.11.015_b0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0167-8140(99)00087-0","article-title":"Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial CHART Steering committee","volume":"52","author":"Saunders","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0010","unstructured":"Lung cancer and smoking statistics \u2013 key facts. Cancer Research UK Website. http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/lung."},{"key":"10.1016\/j.radonc.2015.11.015_b0015","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z","article-title":"Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group","volume":"59","author":"Perez","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2015.11.015_b0020","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radio-chemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2005.02.010","article-title":"High-dose radiation improved local tumor control and overall survival in patients with inoperable\/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study","volume":"63","author":"Kong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0030","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2012.41.6677","article-title":"hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis","volume":"30","author":"LePechoux","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2015.11.015_b0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study","volume":"1","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0040","series-title":"The diagnosis and treatment of lung cancer, update","author":"National Collaborating Centre for Acute Care","year":"2011"},{"key":"10.1016\/j.radonc.2015.11.015_b0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced Non Small Cell Lung Carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0050","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/bjc.1998.678","article-title":"Experience with dose escalation using CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week End Less) in non-small cell lung cancer","volume":"78","author":"Saunders","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2015.11.015_b0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0360-3016(99)00364-8","article-title":"Non small cell lung tumors repopulate rapidly during radiation therapy [Letter to the editor]","volume":"46","author":"Fowler","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2003.09.006","article-title":"Escalated dose for non-small cell lung cancer with accelerated hypofractionated three dimensional conformal radiation therapy","volume":"71","author":"Thirion","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2006.04.034","article-title":"Final results of a phase I\/II dose escalation trial in non small cell lung cancer using three-dimensional conformal radiotherapy","volume":"66","author":"Belderbos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.radonc.2012.09.008","article-title":"Is high dose stereotactic body radiotherapy (SBRT) for stage I Non Small Cell lung Cancer (NSCLC) overkill? A systematic review","volume":"105","author":"Baardwijk","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0080","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ijrobp.2010.06.053","article-title":"Induction chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART): the MRC INCH randomised trial","volume":"81","author":"Hatton","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0090","unstructured":"CONVERT Concurrent ONce-daily VErsus twice-daily RadioTherapy: a 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status. ISRCTN 91927162."},{"key":"10.1016\/j.radonc.2015.11.015_b0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.clon.2012.03.009","article-title":"Stereotactic conformal radiotherapy in Non small cell lung cancer \u2013 an overview","volume":"24","author":"Munshi","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0100","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereo -tactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.30.0731","article-title":"Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis","volume":"28","author":"Palma","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0110","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/S0167-8140(15)30671-X","article-title":"SPACE \u2013 a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC","volume":"111","author":"Nyman","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0115","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0167-8140(15)30170-5","article-title":"Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for NSCLC: Experience from nine UK centres","volume":"111","author":"Bradshaw","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ijrobp.2008.01.033","article-title":"The routine use of Continuous, Hyper-fractionated, Accelerated Radiotherapy (CHART) for Non-Small Cell Lung Cancer: a five centre experience","volume":"72","author":"Din","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0360-3016(00)01374-2","article-title":"A new approach to dose escalation in non-small cell lung cancer","volume":"49","author":"Mehta","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clon.2008.12.011","article-title":"Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement","volume":"21","author":"Fenwick","year":"2009","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.radonc.2011.06.031","article-title":"Final results of the randomised phase III CHART-WEL trial (ARO 97\u20131) comparing hyper-fractionated accelerated vs conventionally fractionated radiotherapy in non-small-cell lung cancer (NSCLC)","volume":"100","author":"Baumann","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2012.12.008","article-title":"GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial","volume":"106","author":"Soliman","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0145","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0360-3016(02)03986-X","article-title":"Comparing different NTCP models that predict the incidence of radiation pneumonitis","volume":"55","author":"Seppenwoolde","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clon.2005.07.016","article-title":"The use of lung dose volume histograms in predicting post-radiation pneumonitis after non-conventionally fractionated radiotherapy for thoracic carcinoma","volume":"17","author":"Clenton","year":"2005","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0155","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/clon.2002.0117","article-title":"From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome","volume":"2002","author":"Bentzen","year":"2002","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0160","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijrobp.2008.02.008","article-title":"Early mucosal reactions during and after head-and-neck radiotherapy: dependence of treatment tolerance on radiation dose and schedule durations","volume":"71","author":"Fenwick","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.11.015_b0165","first-page":"S190","article-title":"IDEAL-CRT: Isotoxic Dose Escalation and Acceleration in Lung Cancer Chemo-Radiotherapy. A phase I\/II trial of dose-escalated radiotherapy and concurrent chemotherapy in patients with stage II or III non-small cell lung cancer","volume":"8","author":"Landau","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2015.11.015_b0170","unstructured":"A phase I\/II trial of isotoxic accelerated radiotherapy in the treatment of patients with non-small cell lung cancer. ISRCTN74841904."},{"key":"10.1016\/j.radonc.2015.11.015_b0175","unstructured":"Isotoxic Intensity Modulated Radiotherapy (IMRT) in stage III non small cell lung cancer (NSCLC) \u2013 A feasibility study. ISRCTN."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015006209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015006209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T20:42:23Z","timestamp":1599943343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015006209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0167814015006209"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.11.015","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous hyperfractionated accelerated radiotherapy \u2013 Escalated dose (CHART-ED): A phase I study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}